Suppr超能文献

评估治疗性疫苗与贝那唑嗪联合治疗克氏锥虫慢性感染。

Assessment of a combined treatment with a therapeutic vaccine and benznidazole for the Trypanosoma cruzi chronic infection.

机构信息

Facultad de Bioquímica y Ciencias Biológicas, Universidad Nacional del Litoral, Santa Fe, Argentina.

Facultad de Ciencias Médicas, Universidad Nacional del Litoral, Santa Fe, Argentina.

出版信息

Acta Trop. 2022 May;229:106334. doi: 10.1016/j.actatropica.2022.106334. Epub 2022 Jan 29.

Abstract

The difficulties encountered in achieving treatments for chronic Chagas disease have promoted the investigation of new therapeutic strategies. In this study, we used two murine models of Trypanosoma cruzi chronic infection to determine the usefulness of applying a therapeutic vaccine alone or followed by benznidazole (Bz) chemotherapy. A vaccine formulation based on an N-terminal fragment of Trans-sialidase (TS) and Immunostimulant Particle Adjuvant (ISPA) - TSNt-ISPA was obtained. Firstly, the immunogenicity and protective capacity of TSNt-ISPA was demonstrated as a prophylactic formulation in an acute model of infection. Later, the formulation was assessed as a therapeutic vaccine alone or combined with (Bz) using two models of chronic infection. BALB/c mice chronically infected with Sylvio X10/4 or Tulahuen cl2 T. cruzi strains were not treated as control or treated only with the therapeutic vaccine TSNt-ISPA, with a combined treatment TSNt-ISPA+Bz (Bz applied after the vaccine), or only with Bz. The vaccination schedule consisted of TSNt-ISPA administration at days110, 120, and 130 post-infection (pi) and Bz administration was performed daily from day 140 to 170 pi. At day 273 pi, electrocardiographic (ECG) parameters, heart parasite load, myocarditis, and heart fibrosis were assessed. In both models, therapeutic administration of TSNt-ISPA reduced ECG alterations and the cardiac tissue damage observed in the chronic phase. Moreover, vaccine treatment significantly decreased heart parasite load in both Sylvio X10/4 and Tulahuen cl2 infected mice. The combined treatment, but not Bz or vaccine administration alone, allowed to restore ECG parameters in Tulahuen cl2 infected mice. The results indicate the usefulness of the therapeutic TSNt-ISPA formulation in BALB/c mice chronically infected with Sylvio X10/4 or Tulahuen cl2 strain. For the mice infected with T. cruzi Tulahuen cl2 strain, the combined treatment with the vaccine and Bz had a more positive effect on the course of heart disease than the individual treatments with the vaccine or Bz alone.

摘要

在实现慢性恰加斯病治疗方面所遇到的困难,促使人们去探索新的治疗策略。在本研究中,我们使用了两种慢性感染克氏锥虫的小鼠模型,以确定单独应用治疗性疫苗或在贝那唑啉(Bz)化疗后应用该疫苗的有用性。我们获得了一种基于转涎酸酶(TS)N 端片段和免疫刺激粒子佐剂(ISPA)的疫苗制剂 TSNt-ISPA。首先,我们证明了 TSNt-ISPA 作为一种预防性制剂在急性感染模型中的免疫原性和保护能力。之后,我们评估了 TSNt-ISPA 作为一种单独的治疗性疫苗,或与(Bz)联合应用于两种慢性感染模型的效果。BALB/c 小鼠慢性感染 Sylvio X10/4 或 Tulahuen cl2 克氏锥虫株,作为对照未予治疗,或仅用治疗性疫苗 TSNt-ISPA 治疗,或用 TSNt-ISPA+Bz 联合治疗(疫苗接种后应用 Bz),或仅用 Bz 治疗。疫苗接种方案包括在感染后第 110、120 和 130 天给予 TSNt-ISPA 接种,Bz 从第 140 天到第 170 天每天给药。在第 273 天,评估心电图(ECG)参数、心脏寄生虫负荷、心肌炎和心脏纤维化。在两种模型中,TSNt-ISPA 的治疗性给药均降低了慢性期观察到的 ECG 改变和心脏组织损伤。此外,疫苗治疗显著降低了 Sylvio X10/4 和 Tulahuen cl2 感染小鼠的心脏寄生虫负荷。联合治疗(而非 Bz 或疫苗单独治疗)使 Tulahuen cl2 感染小鼠的 ECG 参数得以恢复。结果表明,治疗性 TSNt-ISPA 制剂在 Sylvio X10/4 或 Tulahuen cl2 株慢性感染的 BALB/c 小鼠中是有用的。对于感染 T. cruzi Tulahuen cl2 株的小鼠,疫苗和 Bz 的联合治疗对心脏病进程的影响优于疫苗或 Bz 单独治疗。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验